title: The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To evaluate the effects of metformin on the ovarian stromal blood perfusion in the patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Twenty-five women with PCOS who underwent a Doppler examination of the ovarian stroma was evaluated; hormonal, anthropometric, and biochemical parameters of patients were determined. After the patients were treated with 850 mg metformin twice a day for 6 months, the same parameters were evaluated in the same patients.
  
  
  RESULTS
  After metformin treatment, although pulsatility index (PI) was increased from 1.80 +/- 1.23, 1.84 +/- 1.28 to 2.20 +/- 1.10, 2.19 +/- 0.83 in the right and left ovary, respectively, and resistance index was increased from 0.84 +/- 0.25, 0.83 +/- 0.23 to 1.16 +/- 0.37, 1.10 +/- 0.26 in the right and left ovary respectively (P < 0.05), peak systolic velocity (PSV) was decreased from 12.30 +/- 1.72, 12.34 +/- 1.55 to 10.25 +/- 0.97, 10.53 +/- 1.33 in the right and left ovary respectively (P < 0.05). PI and RI did not show any difference between the homeostatic model assessment insulin resistance index (HOMA-IR) >or= 2.38 and HOMA-IR < 2.38 groups before and after metformin treatment (P > 0.05). However, PSV was decreased significantly from 13.05 +/- 1.35, 12.82 +/- 2.02 to 11.03 +/- 0.71, 10.25 +/- 0.42 in HOMA-IR >or= 2.38 group in the right and left ovary, respectively, and PSV was decreased from 11.50 +/- 2.67, 11.28 +/- 0.26 to 9.10 +/- 0.58, 9.28 +/- 0.25 in HOMA-IR < 2.38 group in the right and left ovary, respectively, before and after metformin treatment (P < 0.05). PSV for both ovaries were positively correlated with HOMA scores before and after metformin treatment [(r = 0.713, P = 0.000; r = 0.617, P = 0.04 and r = 0.635, P= 0.03; r = 0.483, P = 0.031 respectively].
  
  
  CONCLUSIONS
  Metformin treatment affected ovarian stromal blood flow in PCOS patients.
authors.affiliation: Obstetrics and Gynecology Department, Baskent University Faculty of Medicine, Selcuklu Konya, Turkey. eparlakyigit@yahoo.com
authors.forename: Emel Ebru
authors.initials: EE
authors.lastname: Ozcimen
authors.forename: Ayla
authors.initials: A
authors.lastname: Uckuyu
authors.forename: Faika Ceylan
authors.initials: FC
authors.lastname: Ciftci
authors.forename: Hulusi Bulent
authors.initials: HB
authors.lastname: Zeyneloglu
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use; D010053:Ovary / Q000098:blood supply* / Q000000981:diagnostic imaging; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011446:Prospective Studies; D012039:Regional Blood Flow / Q000187:drug effects*; D018615:Ultrasonography, Doppler, Color; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin